• 52,741+ CME Conference Registrations Sold
  • 158,223+ Medical Conferences
  • 285 Specialties
  • 11,425 Organizers
  • 157,142 Speakers
  • 159 Countries
  • 4,803 Cities

Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity is organized by CME Outfitters, LLC.

Live Webcast: Thursday, June 11, 2020 | 6:30 PM - 8:00 PM ET
Credit Expiration Date: Friday, June 11, 2021

This activity offers CE credit for:
•  Physicians (CME)
•  Nurses (CNE)
•  Pharmacists (ACPE)
•  ABIM (MOC)
•  Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.

Credit Information

CME Credit (Physicians):

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs).

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Need
The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, and clinical data for both show promise for patients with SPMS.

However, despite these advances, studies have shown that gaps in knowledge and performance exist among neurologists and their care team that pose a barrier to the integration of new and emerging therapies to treat MS in clinical practice.

This CME Outfitters Live and On Demand webcast will include an interactive, case-based panel discussion featuring expert faculty who will discuss the symptoms and clinical features of progressive MS, summarize its immunopathology and the mechanisms of action (MOAs) of new and investigational disease modifying therapies (DMTs), and evaluate the latest clinical evidence on the efficacy and safety of new and emerging therapies for SPMS and PPMS.

Learning Objectives
At the end of this CE activity, participants should be able to:
•  Recognize the symptoms and clinic features of progressive MS.
•  Summarize the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
•  Evaluate the latest clinic evidence of new and emerging therapies for SPMS and PPMS and engage patients in the shared decision-making process.
•  Integrate strategies for SDM to deliver patient-centered care.

The following learning objectives pertain only to those requesting CNE or CPE credit:
•  Recognize the symptoms and clinical features of progressive MS.
•  Summarize the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
•  Summarize the latest clinical evidence on efficacy and safety of new and emerging therapies for SPMS and PPMS.

Intended Audience

Neurologists, MS specialists, PAs, NPs, nurses, and pharmacists.

Activity Payment Details

Activity Fee : NA
Interested

Rate this CME (Min 1 - Max 5)

Duration:
Fee and expenses:
CME credits:
Program contents:
Networking:
Write Your Review

Reviews Given by Professionals

No Reviews available. Be the first to write a review.

Privacy Policy

Read eMedEvents Privacy Policy

Organizer(s)

CME Outfitters, LLC

View Organizer Details

Help

877.263.7767

Convert
Live to Virtual Conference

Market your online event to Million plus Healthcare professionals.

Recommended